Tech Company Financing Transactions
Teclison Funding Round
WTT Investment and private investors invested in a $5.9 million capital raise for Teclison. This venture round closed on 2/25/2022.
Transaction Overview
Company Name
Announced On
2/25/2022
Transaction Type
Venture Equity
Amount
$5,900,000
Round
Undisclosed
Investors
WTT Investment (Lead Investor)
Proceeds Purpose
The proceeds from the financing will further advance clinical studies of the company's lead product candidate, TEC-001, a potential first-in-class therapeutic agent designed to induce tumor necrosis and enhance immune checkpoint inhibitors in solid cancers with liver metastasis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
26 Park St. 100
Montclair, NJ 07042
USA
Montclair, NJ 07042
USA
Phone
Undisclosed
Website
Email Address
Overview
Teclison's goal is to solve the poor prognosis for solid tumors with liver metastasis. Liver metastasis is also the most common cause of cancer death. Our mission is to develop new drugs to treat cancer and other diseases with strong unmet medical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ray Lee
Vice President
Michael Bond
Browse more venture capital transactions:
Prev: 2/25/2022: Digital Infrastructure venture capital transaction
Next: 2/25/2022: Haul venture capital transaction
Share this article
About Our VC Transactions Data
We record every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs